학술논문
The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.
Document Type
article
Author
Alain Hendlisz; Amelie Deleporte; Thierry Delaunoit; Raphaël Maréchal; Marc Peeters; Stéphane Holbrechts; Marc Van den Eynde; Ghislain Houbiers; Bertrand Filleul; Jean-Luc Van Laethem; Sarah Ceyssens; Anna-Maria Barbuto; Renaud Lhommel; Gauthier Demolin; Camilo Garcia; Hazem El Mansy; Lieveke Ameye; Michel Moreau; Thomas Guiot; Marianne Paesmans; Martine Piccart; Patrick Flamen
Source
PLoS ONE, Vol 10, Iss 9, p e0138341 (2015)
Subject
Language
English
ISSN
1932-6203
Abstract
Tumoral heterogeneity is a major determinant of resistance in solid tumors. FDG-PET/CT can identify early during chemotherapy non-responsive lesions within the whole body tumor load. This prospective multicentric proof-of-concept study explores intra-individual metabolic response (mR) heterogeneity as a treatment efficacy biomarker in chemorefractory metastatic colorectal cancer (mCRC).Standardized FDG-PET/CT was performed at baseline and after the first cycle of combined sorafenib (600mg/day for 21 days, then 800mg/day) and capecitabine (1700 mg/m²/day administered D1-14 every 21 days). MR assessment was categorized according to the proportion of metabolically non-responding (non-mR) lesions (stable FDG uptake with SUVmax decrease